BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pharmacogenetics
,
Lipitor
,
rs3825942
,
BRCA1
,
calcium channel activity
,
Lung cancer
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
disorder al amyloidosis
Summary
General Info
Curated Studies
Most Correlated Studies
Myeloma ALMC1 cells with amyloidosis depleted of immunoglobulin light chain
Clonal plasma cells from bone marrow of amyloidosis subjects
Whole blood from patients with periodic fever syndromes
Cyclin D1 in AL Amyloidosis Baseline Plasma Cells
Brain cortices from APP NL-G-F/NL-G-F and 3xTg-AD-H mouse models of Alzheimer's disease
Explore Curated Studies Results
Literature
Most Relevant Literature
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloi…
Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm.
Bad players in AL amyloidosis in the current era of treatment.
Assessment of Tp-Te interval in patients with cardiac AL amyloidosis.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Allo SCT in Amyloidosis Non-interventional Study
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ